Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration

MLA

Takahito Saiki, et al. “Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.” Breast Cancer (Tokyo, Japan), vol. 2, no. 2, Oct. 1995. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2cc1f0c7f6987195719f8325d780aa8f&authtype=sso&custid=ns315887.

APA

Takahito Saiki, Makoto Fukuda, Kenichirou Baba, Reiki Nishimura, Masakazu Matsuda, Hiroya Yamashita, Yukio Matsuoka, Akihiro Higuchi, & Kazuharu Nagao. (1995). Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration. Breast Cancer (Tokyo, Japan), 2(2).

Chicago

Takahito Saiki, Makoto Fukuda, Kenichirou Baba, Reiki Nishimura, Masakazu Matsuda, Hiroya Yamashita, Yukio Matsuoka, Akihiro Higuchi, and Kazuharu Nagao. 1995. “Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.” Breast Cancer (Tokyo, Japan) 2 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2cc1f0c7f6987195719f8325d780aa8f&authtype=sso&custid=ns315887.